---
id: tapeworms-flukes-schistosomiasis_102
category: organisms
tags: [tapeworms, taenia, cysticercosis, neurocysticercosis, schistosomiasis, praziquantel]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Tapeworms (Cestodes) & Flukes: Taenia, Cysticercosis, Schistosomiasis

**Q:** What are the clinical features, diagnosis, and treatment of intestinal tapeworms (Taenia), cysticercosis/neurocysticercosis, and schistosomiasis?

**A:**

## OVERVIEW

| **Organism** | **Transmission** | **Key Clinical Feature** | **Diagnosis** | **Treatment** |
|--------------|------------------|--------------------------|---------------|---------------|
| ***Taenia solium*** (pork tapeworm) | **Undercooked pork** (tapeworm)<br>**Fecal-oral eggs** (cysticercosis) | **Cysticercosis** (CNS, muscle) | Serology, CT/MRI (neurocysticercosis) | **Praziquantel** (taeniasis)<br>**Albendazole** (neurocysticercosis) |
| ***Taenia saginata*** (beef tapeworm) | Undercooked beef | Asymptomatic (proglottids in stool) | Stool O&P (eggs, proglottids) | Praziquantel (single dose) |
| ***Schistosoma* species** (flukes) | **Freshwater exposure** (cercariae penetrate skin) | **Katayama fever**, **hematuria** (S. haematobium), **hepatosplenomegaly** (S. mansoni/japonicum) | Serology, stool/urine O&P (eggs) | **Praziquantel** (40-60 mg/kg divided doses) |

**Key Point:** **T. solium = neurocysticercosis** (most important), **Schistosomiasis = freshwater exposure**

---

## 1. TAENIASIS (INTESTINAL TAPEWORM INFECTION)

### **Organisms:**
- ***Taenia solium*** (pork tapeworm)
- ***Taenia saginata*** (beef tapeworm)

---

### ***Taenia solium* (Pork Tapeworm):**

**Transmission:**
- **Undercooked pork** → **Tapeworm** (intestinal infection - taeniasis)
- **Fecal-oral eggs** (*T. solium* eggs) → **Cysticercosis** (tissue infection)

**Clinical Features (Taeniasis):**
- **Asymptomatic** (most common)
- **Abdominal discomfort, nausea**
- **Proglottids in stool** (gravid segments)

**Key Point:** ***T. solium* = can cause BOTH taeniasis (intestinal) AND cysticercosis** (tissue - from ingesting eggs)

---

### ***Taenia saginata* (Beef Tapeworm):**

**Transmission:**
- **Undercooked beef** → **Tapeworm** (intestinal infection)

**Clinical Features:**
- **Asymptomatic** (most common)
- **Proglottids in stool** (may migrate out of anus - perianal itching)

**Key Point:** ***T. saginata* = tapeworm ONLY** (does NOT cause cysticercosis in humans)

---

### **Diagnosis (Taeniasis):**

| **Test** | **Specimen** | **Notes** |
|----------|--------------|-----------|
| **Stool O&P** | Stool | **Eggs** (indistinguishable between *T. solium* and *T. saginata*)<br>**Proglottids** (can differentiate species by counting uterine branches) |

---

### **Treatment (Taeniasis):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Praziquantel** (preferred) | **5-10 mg/kg PO x 1 dose** | **Single dose** (10 mg/kg more effective) |
| **OR Niclosamide** | **2 g PO x 1 dose** (adults) | **Single dose** |

**Key Point:** **Praziquantel = single dose** for taeniasis

---

## 2. CYSTICERCOSIS / NEUROCYSTICERCOSIS

**Definition:**
- **Cysticercosis:** Tissue infection with **larval stage** of ***T. solium***
- **Neurocysticercosis:** Cysticercosis of the **CNS** (most important manifestation)

**Transmission:**
- **Fecal-oral ingestion** of ***T. solium* eggs** (NOT undercooked pork - that causes tapeworm)
- **Autoinfection** (person with intestinal tapeworm ingests own eggs)

**Epidemiology:**
- **Endemic:** Latin America, sub-Saharan Africa, Asia
- **Leading cause of acquired epilepsy** in endemic areas
- **US:** Mostly immigrants/travelers

---

### **Clinical Features:**

**Location of Cysts Determines Symptoms:**

---

#### **A. Parenchymal Neurocysticercosis (Most Common - 60-90%):**

**Cysts in brain parenchyma (cortex)**

**Clinical Features:**
- **Seizures** (most common presentation - 70-90%)
  - **Focal or generalized**
- **Headache**
- **Cognitive impairment** (chronic)

**Stages of Cyst Evolution:**
1. **Vesicular** (viable cyst - no inflammation)
2. **Colloidal** (degenerating cyst - inflammation, edema, enhancement)
3. **Granular-nodular** (further degeneration, decreased edema)
4. **Calcified** (inactive, no edema, may still cause seizures)

**Key Point:** **Seizures = most common presentation** (parenchymal cysts)

---

#### **B. Extraparenchymal Neurocysticercosis:**

---

##### **1. Intraventricular Cysticercosis:**

**Cysts in ventricles** (especially 4th ventricle)

**Clinical Features:**
- **Hydrocephalus** (obstructive - cyst blocks CSF flow)
- **Increased intracranial pressure** (headache, vomiting, papilledema)
- **Sudden death** (if acute obstruction)

---

##### **2. Subarachnoid Cysticercosis (Racemose Form):**

**Cysts in subarachnoid space** (basilar cisterns)

**Clinical Features:**
- **Chronic meningitis**
- **Hydrocephalus** (communicating - arachnoiditis)
- **Stroke** (vasculitis from inflammation)
- **Cranial nerve palsies**

**Key Point:** **Racemose = worst prognosis** (large, irregular cysts in cisterns)

---

##### **3. Spinal Cysticercosis (Rare):**

**Clinical Features:**
- **Radiculopathy, myelopathy**
- **Paraplegia** (if cord compression)

---

### **Diagnosis:**

**Imaging:**

**CT Brain (Initial):**
- **Cysts:** Round, hypodense lesions with **"dot sign"** (scolex - pathognomonic)
- **Calcifications** (inactive cysts)
- **Ring-enhancing lesions** (if degenerating - colloidal stage)

**MRI Brain (Preferred for Characterization):**
- **Better visualization** of cyst stages, intraventricular/subarachnoid cysts
- **FLAIR:** Perilesional edema
- **T1 post-gadolinium:** Ring enhancement (degenerating cysts)

**Key Point:** **"Dot sign" = scolex** (pathognomonic for cysticercosis)

---

**Serology:**

| **Test** | **Sensitivity** | **Notes** |
|----------|-----------------|-----------|
| **Enzyme-linked immunoelectrotransfer blot (EITB)** | **~98%** (if ≥2 cysts)<br>**~60%** (if single cyst) | **Preferred serologic test**<br>Lower sensitivity if calcified cysts only |

**Key Point:** **Serology (EITB) highly sensitive** if multiple viable cysts

---

**CSF (If Obtained):**
- **Eosinophilia** (10-20%)
- **Lymphocytic pleocytosis**
- **Elevated protein**
- **Low glucose** (if arachnoiditis)

---

### **Treatment:**

**General Principles:**
- **Antiparasitic treatment NOT indicated for ALL neurocysticercosis**
- **Risks/benefits** must be weighed (inflammation from dying cysts can worsen symptoms)

---

#### **Parenchymal Neurocysticercosis:**

**Indications for Antiparasitic Treatment:**
- **Viable (vesicular) or degenerating (colloidal) cysts**
- **NOT indicated** if:
  - **Calcified cysts only** (inactive - no benefit)
  - **Single degenerating cyst** (may resolve spontaneously)

**Regimen:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Albendazole** (preferred) | **15 mg/kg/day PO divided BID** (max 800 mg BID) | **10-14 days** |
| **OR Praziquantel** | **50 mg/kg/day PO divided TID** | **10-14 days** |

**Adjunctive Corticosteroids (ESSENTIAL):**
- **Dexamethasone** 6 mg PO/IV daily (or equivalent)
- **Start 1-2 days before antiparasitic therapy** → Continue during treatment → Taper
- **Reduce inflammation** from dying cysts (prevent seizures, edema)

**Antiepileptic Drugs (AEDs):**
- **Indicated if seizures**
- **Duration:** Variable (may need lifelong if calcified cysts/recurrent seizures)

**Key Point:** **Albendazole + corticosteroids** for viable/degenerating parenchymal cysts

---

#### **Extraparenchymal Neurocysticercosis (Intraventricular/Subarachnoid):**

**Treatment:**

| **Approach** | **Details** |
|--------------|-------------|
| **Surgical removal** | **Preferred** for intraventricular cysts (especially if obstructive hydrocephalus)<br>**Endoscopic removal** or **ventriculoperitoneal shunt** (if hydrocephalus) |
| **Antiparasitic therapy** | **Prolonged course** (weeks to months)<br>**Albendazole** + **Corticosteroids**<br>**Consider in addition to surgery** |

**Key Point:** **Surgery = preferred** for intraventricular cysts (remove cyst + relieve hydrocephalus)

---

#### **Calcified Cysts (Inactive):**

**Treatment:**
- **NO antiparasitic therapy** (inactive - no benefit)
- **Antiepileptic drugs** if seizures

---

## 3. SCHISTOSOMIASIS (BLOOD FLUKES)

**Organisms:** *Schistosoma* species (trematodes/flukes)
- ***S. mansoni*** (Africa, Latin America, Middle East)
- ***S. japonicum*** (Asia - China, Philippines)
- ***S. haematobium*** (Africa, Middle East)

**Transmission:**
- **Freshwater exposure** (swimming, bathing in endemic areas)
- **Cercariae** (free-swimming larvae) **penetrate intact skin**

**Epidemiology:**
- **~200 million infected** worldwide
- **Endemic:** Sub-Saharan Africa (>90%), Latin America, Asia, Middle East

---

### **Life Cycle:**

1. **Cercariae** in freshwater **penetrate skin** → Bloodstream
2. **Migrate to liver** → Mature into adult worms (male + female pairs)
3. **Migrate to final location:**
   - ***S. mansoni*, *S. japonicum*:** **Mesenteric veins** (intestine)
   - ***S. haematobium*:** **Vesical plexus** (bladder)
4. **Lay eggs** → Eggs **penetrate** into intestine/bladder → **Excreted** in stool/urine
5. **Eggs hatch** in freshwater → **Miracidia** infect **snails** → Cercariae released

**Key Point:** **Cercariae penetrate skin** (freshwater exposure)

---

### **Clinical Features:**

---

#### **A. Acute Schistosomiasis (Katayama Fever):**

**Timing:** 2-8 weeks after exposure

**Clinical Features:**
- **Fever, chills, rigors**
- **Urticaria, angioedema**
- **Cough, dyspnea** (eosinophilic pneumonitis)
- **Hepatosplenomegaly, lymphadenopathy**
- **Diarrhea, abdominal pain**
- **Eosinophilia** (marked)

**Key Point:** **Katayama fever = acute hypersensitivity** to migrating schistosomulae (serum sickness-like)

---

#### **B. Chronic Schistosomiasis:**

---

##### ***S. haematobium* (Urogenital Schistosomiasis):**

**Clinical Features:**
- **Hematuria** (terminal - at end of urination) - pathognomonic
- **Dysuria, frequency**
- **Hydronephrosis** (ureteral obstruction from fibrosis)
- **Bladder fibrosis, calcification** ("calcified bladder" on X-ray)
- **Bladder cancer** (squamous cell carcinoma - long-term complication)

**Key Point:** ***S. haematobium* = hematuria** + bladder fibrosis + **squamous cell bladder cancer risk**

---

##### ***S. mansoni*, *S. japonicum* (Intestinal/Hepatosplenic Schistosomiasis):**

**Clinical Features:**

**Intestinal:**
- **Bloody diarrhea, abdominal pain**
- **Colonic polyps** (pseudopolyps from granulomas)

**Hepatosplenic (Most Important):**
- **Periportal fibrosis** (Symmers' "pipestem" fibrosis)
- **Portal hypertension** (presinusoidal)
  - **Splenomegaly** (massive)
  - **Esophageal varices** (hematemesis)
  - **Ascites**
- **NORMAL liver function** (hepatocytes spared)

**Key Point:** **Periportal fibrosis → portal hypertension** with **NORMAL liver function** (unlike cirrhosis)

---

#### **C. Other Complications:**

- **Pulmonary hypertension** (eggs embolize to lungs → granulomas)
- **CNS schistosomiasis** (eggs in brain/spinal cord → seizures, myelopathy)

---

### **Diagnosis:**

**Serology (Travel/Early Infection):**

| **Test** | **Sensitivity** | **Notes** |
|----------|-----------------|-----------|
| **Antibody testing (ELISA, IFA)** | **>90%** | **Preferred for travelers/early infection**<br>Cannot distinguish active vs past infection |

**Stool/Urine O&P (Chronic Infection):**

| **Test** | **Specimen** | **Sensitivity** | **Notes** |
|----------|--------------|-----------------|-----------|
| **Microscopy** | Stool (*S. mansoni*, *S. japonicum*)<br>Urine (*S. haematobium*) | **Variable** (depends on worm burden) | Look for **eggs** (characteristic lateral spine - *S. mansoni*, terminal spine - *S. haematobium*) |
| **Kato-Katz** | Stool | **Quantitative** (eggs/gram) | Measure infection intensity |

**Key Point:** **Serology = best for travelers** (before egg production), **Stool/urine O&P** for chronic infection

---

**Important Timing:**
- **Wait 6-8 weeks after last exposure** before treatment (praziquantel ineffective against immature worms)

---

### **Treatment:**

**First-Line:**

| **Agent** | **Species** | **Dosing** | **Duration** |
|-----------|-------------|------------|--------------|
| **Praziquantel** (only drug for schistosomiasis) | ***S. mansoni*, *S. haematobium*** | **40 mg/kg PO x 1 dose** (or 20 mg/kg PO BID x 1 day) | **Single day** |
| **Praziquantel** | ***S. japonicum*, *S. mekongi*** | **60 mg/kg/day PO divided TID** | **Single day** |

**Follow-Up:**
- **Repeat stool/urine O&P** at 1-2 months post-treatment (confirm cure)
- **Repeat treatment** if positive (may need 2-4 weeks after first treatment if lightly infected)

**Key Point:** **Praziquantel = only drug** for schistosomiasis (single-day treatment)

---

**Adjunctive Treatment:**

**Katayama Fever (Acute):**
- **Corticosteroids** (prednisone 20-40 mg daily x 5 days, taper)
- **Delay praziquantel** until after acute phase (ineffective against immature worms)

**Hepatosplenic Schistosomiasis:**
- **Praziquantel** (kill worms)
- **Manage portal hypertension:** Beta-blockers, endoscopic variceal ligation, TIPS (if refractory)

---

### **Prevention:**

- **Avoid freshwater exposure** in endemic areas (swimming, bathing)
- **Towel dry vigorously** after accidental exposure (may remove some cercariae)

---

## COMPARISON TABLE

| **Feature** | **Taeniasis** | **Cysticercosis/Neurocysticercosis** | **Schistosomiasis** |
|-------------|---------------|--------------------------------------|---------------------|
| **Organism** | *T. solium* (pork), *T. saginata* (beef) | ***T. solium* larvae** (tissue stage) | *Schistosoma* species (flukes) |
| **Transmission** | Undercooked meat | **Fecal-oral eggs** | **Freshwater** (cercariae penetrate skin) |
| **Key clinical feature** | Asymptomatic (proglottids in stool) | **Seizures** (parenchymal NCC) | **Hematuria** (*S. haematobium*), **portal hypertension** (*S. mansoni*/*japonicum*) |
| **Diagnosis** | Stool O&P (eggs, proglottids) | **Imaging** (CT/MRI - "dot sign"), serology (EITB) | **Serology** (travelers), stool/urine O&P (eggs) |
| **Treatment** | **Praziquantel** 5-10 mg/kg x 1 | **Albendazole** 15 mg/kg/day x 10-14 days + **corticosteroids** | **Praziquantel** 40-60 mg/kg x 1 day |

---

**Mnemonic: "T. solium = Two Diseases (Tapeworm + Cysticercosis)"**
- **T**. solium
- **T**apeworm (undercooked pork)
- **C**ysticercosis (fecal-oral eggs)

**Mnemonic: "NCC = Seizures + Dot Sign (Scolex)"**
- **N**eurocysticercosis
- **S**eizures (most common presentation)
- **D**ot sign = scolex (pathognomonic)

**Mnemonic: "Schistosoma = Swim in Snail Water (Cercariae)"**
- **S**chistosoma
- **S**wim in freshwater
- **C**ercariae penetrate skin

**Mnemonic: "S. haematobium = Hematuria (Bladder Cancer Risk)"**
- **S**. haematobium
- **H**ematuria (terminal)
- **B**ladder cancer (squamous cell)

**Clinical Pearls:**
- ***T. solium* = both taeniasis (tapeworm) AND cysticercosis** (from ingesting eggs)
- ***T. saginata* = tapeworm ONLY** (no cysticercosis in humans)
- **Neurocysticercosis = leading cause of acquired epilepsy** in endemic areas
- **Seizures = most common presentation** of parenchymal NCC
- **"Dot sign" = scolex** (pathognomonic for cysticercosis on CT/MRI)
- **Serology (EITB) highly sensitive** if multiple viable cysts (98%)
- **Albendazole + corticosteroids** for viable/degenerating parenchymal NCC
- **Surgery preferred** for intraventricular cysts (remove cyst + relieve hydrocephalus)
- **NO antiparasitic therapy** for calcified cysts (inactive)
- **Katayama fever** = acute schistosomiasis (serum sickness-like - 2-8 weeks post-exposure)
- ***S. haematobium* = hematuria** + bladder fibrosis + **squamous cell bladder cancer risk**
- ***S. mansoni*/*japonicum* = periportal fibrosis → portal hypertension** with **NORMAL liver function**
- **Serology = best for travelers** (before egg production)
- **Wait 6-8 weeks after last exposure** before praziquantel (ineffective against immature worms)
- **Praziquantel = only drug** for schistosomiasis (40-60 mg/kg single day)

**Media:** None

**Sources:** [CDC Yellow Book 2024 - Taeniasis, Cysticercosis], [CDC 2024 - Neurocysticercosis clinical care], [IDSA/ASTMH 2017 - Cysticercosis treatment guidelines], [CDC 2024 - Schistosomiasis clinical care], [CDC Yellow Book 2024 - Schistosomiasis], [NEJM 2024 - Neurocysticercosis], [Lancet Infectious Diseases 2024 - Schistosomiasis treatment update]
